Report Date: Thursday, August 6, 2026, before market open | Call at 8:00 a.m. ET Fiscal Quarter: Q3 FY2026 (ended June 30, 2026)
BD is reporting its second full quarter as a standalone "New BD" following the February 9, 2026 spin-off of its former Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation in a Reverse Morris Trust deal. All prior-period comparisons have been recast to reflect that business as discontinued operations, so year-over-year comparisons that mix pre- and post-spin numbers (e.g., versus last year's reported $3.68 EPS) can be misleading — the "clean" comp is against the recast continuing-operations base.
The stock has had a strong run into the print: shares have rallied from the mid-$140s in mid-July to roughly $170 heading into earnings, helped by a wave of sellside positioning — UBS initiated coverage with a Buy rating and a $190 price target, arguing the stock's valuation had compressed and highlighting the post-Waters portfolio as simpler and more focused, with expectations for better medium-term growth and a more shareholder-oriented capital allocation approach. Barclays has also raised its target, and analyst sentiment is described as reasonably constructive: consensus opinion on BDX is a "Moderate Buy," with six of 15 analysts at "Strong Buy" and nine at "Hold," and an average price target of $175 (about 13% implied upside at the time of that survey). A separate estimate from ChartMill pegs the average 12-month target near $187.
| Metric | Consensus | Notes |
|---|---|---|
| Adjusted EPS | ~$3.14–$3.16 | Down 14.7% from $3.68 a year ago on an unadjusted comp basis (skewed by the Life Sciences spin-off) |
| Revenue | ~$4.9B | Consistent with a fiscal Q3 report date of August 6; implies continued low-single-digit organic growth |
| FXN revenue growth | ~2.6% | In line with management's own H2 framing |
Importantly, using BD's own guidance math is more useful than the messy y/y comp: Q1 adjusted EPS was $2.91 and Q2 was $2.90, putting first-half adjusted EPS at $5.81. Full-year guidance of $12.52–$12.72 implies second-half EPS of roughly $6.71–$6.91 — with Q3 typically the softer of the two remaining quarters and Q4 seasonally the strongest.
Q2 was a clean beat-and-raise: revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN, with GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively. Management highlighted that more than 90% of the portfolio was growing mid-single-digits or better, with several "scaled growth platforms" — biologic drug delivery, Advanced Patient Monitoring (APM), PureWick, and Advanced Tissue Regeneration — growing double digits, partially offset by known, deliberate pressure points in Alaris, vaccines, and China (collectively less than 10% of revenue). The company raised full-year adjusted EPS guidance to $12.52–$12.72 while reaffirming low-single-digit revenue growth guidance, and management explicitly said it expects second-half revenue growth to look similar to the first half.
a) Durability of the "known headwinds" narrative. Management has been explicit that Alaris (tough comp vs. the pump remediation upgrade cycle), vaccines (broad industry demand air pocket), and China (VBP/procurement dynamics) are tracking to plan, with the Alaris headwind set to widen to 200 bps in FY27 before disappearing in FY28. Investors will want confirmation these three drags are still playing out as modeled and haven't worsened — especially China, and any incremental read on vaccine order patterns heading into next year.
b) Margin trajectory and tariffs. Q2 adjusted operating margin was 24.2%, down 110 bps y/y, with 160 bps of tariff drag. Full-year guidance still calls for ~25% adjusted operating margin inclusive of tariffs, funded largely by "BD Excellence" productivity (8% in Q2) and a $200 million cost-out program (already at a $150 million run-rate). Watch for updated tariff/resin cost commentary — management has signaled it is assuming oil/resin costs stay elevated into FY27 and is leaning on hedges (~50% of North American resin hedged), multi-sourcing, and pricing actions to offset.
c) The El Paso/ChloraPrep situation. In late April/early May, BD's El Paso facility (which makes ChloraPrep and PurPrep) received an FDA warning letter, prompting a voluntary U.S. ship hold while BD ran additional release testing. BD voluntarily placed ChloraPrep and PurPrep on ship hold in the U.S. in early May, then resumed U.S. shipments after reporting that all added final release tests to date had been acceptable and that no patient safety signals had been identified. The underlying warning letter remains open, and the 10-Q flags that BD believes a loss related to the matter is probable but cannot yet estimate the amount — this is a regulatory overhang worth monitoring for any Q3 revenue/margin impact disclosure or updated reserve.
d) Leadership transition follow-through. Vitor Roque was named permanent CFO in May after serving as interim since fall 2025; this is his second full quarter of prepared remarks as permanent CFO, and continuity of messaging (growth, disciplined capital allocation, transparent guidance) will be a soft but relevant signal. Separately, BD announced in late July that EVP Mike Garrison (Medical Essentials & BioPharma Systems) will retire effective October 2, with BioPharma Systems moving to report directly to CEO Tom Polen — a signal of the strategic importance BD places on the higher-growth, higher-margin GLP-1/biologics-driven BioPharma Systems unit. Expect questions on the search for a new Medical Essentials president and any read-through to segment focus.
e) Capital allocation cadence. BD returned $2.3 billion to shareholders in Q2 (including a $2 billion ASR) and retired $2.1 billion of debt, ending the quarter at ~2.9x net leverage versus a 2.5x long-term target. Management has been explicit that, at current valuation, buybacks rank above tuck-in M&A in priority. Watch for confirmation of continued buyback pace and progress toward the leverage target, as well as any commentary on the "focused" tuck-in M&A pipeline.
f) Growth-platform momentum. GLP-1/biologics (now ~55% of BioPharma Systems revenue, up from 50% previously disclosed), APM (Q2 grew 13.6% reported / 12% FXN), PureWick, Advanced Tissue Regeneration, and the new Pyxis Pro launch (BD's first AI-enabled, cloud-connected dispensing platform, with 75% of early wins being competitive conversions) are the pillars of BD's re-acceleration thesis toward durable mid-single-digit growth. Continued double-digit growth in these platforms would reinforce the bull case that "New BD" is a structurally better-growth, better-margin business than the pre-spin conglomerate.
Entering Thursday's print, BD looks to be executing its "compete, innovate, deliver" playbook reasonably well: broad-based mid-single-digit growth across ~90% of the portfolio, expanding productivity, and a cleaner post-spin story, offset by well-telegraphed and (so far) on-plan headwinds in Alaris, vaccines, and China, plus a live regulatory question mark at El Paso. The setup favors "no surprises" — confirmation that H2 guidance ($12.52–$12.72 full-year adjusted EPS, ~25% operating margin, low-single-digit FXN revenue growth) remains intact, continued double-digit growth in the key platforms (biologics/GLP-1, APM, PureWick, ATR), and clean resolution language on ChloraPrep/El Paso would likely be well received given how far the stock has already run. Any wobble in the "known headwinds are on-plan" narrative, or fresh disclosure on the El Paso matter's financial impact, would be the more likely sources of downside surprise.